(+/-)-Epinephrine bitartrate | 51-42-3

• 物质功能分类: 原料药 - 循环系统用药 - 抗休克血管活性药
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: (+/-)-Epinephrine bitartrate
• 英文别名: racemic epinephrine bitartrate；L-(+)-Epinephrine tartrate；epinephrine bitartrate；Adrenaline bitartrate；Adrenalin*Weinsaeure；2,3-Dihydroxybutanedioic acid; 4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol；2,3-dihydroxybutanedioic acid;4-[1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
• CAS: 51-42-3；636-89-5；1234-55-5；2964-12-7；14479-84-6；19947-47-8；21282-30-4；24351-82-4；40004-76-0；55750-10-2；69207-54-1；104655-01-8
• 化学式: C₄H₆O₆*C₉H₁₃NO₃
• 分子量: 333.295
• InChiKey: YLXIPWWIOISBDD-UHFFFAOYSA-N

物化性质

• 熔点：
  ~155 °C (dec.)
• 溶解度：
  可溶于水中
• 稳定性/保质期：
  稳定存储。避免与碱性物质、氧化剂、铁、铁盐、铜及铜合金接触。

计算性质

• 辛醇/水分配系数(LogP)：
  -1.77
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  188
• 氢给体数：
  8
• 氢受体数：
  10

安全信息

• 危险等级：
  6.1(b)
• 危险品标志：
  T+
• 安全说明：
  S26,S28,S36/37,S45
• 危险类别码：
  R36/37/38,R28
• WGK Germany：
  3
• 海关编码：
  29379000
• RTECS号：
  DO3500000
• 包装等级：
  III
• 危险类别：
  6.1(b)
• 危险品运输编号：
  UN 2811 6.1/PG 1
• 储存条件：
  密封避光保存。

SDS

---

Section 1. Chemical Product and Company Identification
Epinephrine bitartrate Catalog
EP135
Common Name/
Number(s).
Trade Name
CAS# 51-42-3
Manufacturer
RTECS Not available.
SPECTRUM CHEMICAL MFG. CORP.
TSCA TSCA 8(b) inventory:
Epinephrine bitartrate
Commercial Name(s) Not available.
CI# Not available.
Synonym L-Adrenaline
IN CASE OF EMERGENCY
Not available.
Chemical Name
Chemical Family Not available. CALL [phone]
C9H13NO3.C4H6O6
Chemical Formula
SPECTRUM CHEMICAL MFG. CORP.

---

Section 2.Composition and Information on Ingredients
Exposure Limits
TWA (mg/m3) STEL (mg/m3) CEIL (mg/m3)
Name CAS # % by Weight
1) Epinephrine bitartrate 51-42-3 100
Toxicological Data Epinephrine bitartrate:
on Ingredients ORAL (LD50): Acute: 4 mg/kg [Mouse].

---

Section 3. Hazards Identification
Potential Acute Health Effects Very hazardous in case of ingestion, of inhalation. Hazardous in case of skin contact (irritant, permeator), of eye
contact (irritant). Severe over-exposure can result in death.
Potential Chronic Health Very hazardous in case of ingestion, of inhalation.
Hazardous in case of skin contact (irritant, permeator), of eye contact (irritant).
Effects
CARCINOGENIC EFFECTS: Not available.
MUTAGENIC EFFECTS: Not available.
TERATOGENIC EFFECTS: Not available.
DEVELOPMENTAL TOXICITY: Not available.
The substance is toxic to lungs, the nervous system, mucous membranes.
Repeated or prolonged exposure to the substance can produce target organs damage. Repeated exposure to an
highly toxic material may produce general deterioration of health by an accumulation in one or many human
organs.
Epinephrine bitartrate

---

Section 4. First Aid Measures
Eye Contact Check for and remove any contact lenses. Immediately flush eyes with running water for at least 15 minutes,
keeping eyelids open. Cold water may be used. Do not use an eye ointment. Seek medical attention.
Skin Contact After contact with skin, wash immediately with plenty of water. Gently and thoroughly wash the contaminated skin
with running water and non-abrasive soap. Be particularly careful to clean folds, crevices, creases and groin.
Cold water may be used. Cover the irritated skin with an emollient. If irritation persists, seek medical attention.
Wash contaminated clothing before reusing.
Serious Skin Contact Wash with a disinfectant soap and cover the contaminated skin with an anti-bacterial cream. Seek immediate
medical attention.
Inhalation Allow the victim to rest in a well ventilated area. Seek immediate medical attention.
Serious Inhalation Evacuate the victim to a safe area as soon as possible. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, administer oxygen. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Seek medical attention.
Ingestion Do not induce vomiting. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible
indication that the toxic material was ingested; the absence of such signs, however, is not conclusive. Loosen
tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Seek immediate medical attention.
Serious Ingestion
Not available.

---

Section 5. Fire and Explosion Data
Flammability of the Product May be combustible at high temperature.
Auto-Ignition Temperature Not available.
Flash Points Not available.
Flammable Limits Not available.
Products of Combustion These products are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...).
Fire Hazards in Presence of Not available.
Various Substances
Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available.
Risks of explosion of the product in presence of static discharge: Not available.
of Various Substances
SMALL FIRE: Use DRY chemical powder.
Fire Fighting Media
and Instructions LARGE FIRE: Use water spray, fog or foam. Do not use water jet.
Not available.
Special Remarks on
Fire Hazards
Special Remarks on Explosion Not available.
Hazards

---

Section 6. Accidental Release Measures
Small Spill Use appropriate tools to put the spilled solid in a convenient waste disposal container.
Large Spill Use a shovel to put the material into a convenient waste disposal container.
Epinephrine bitartrate

---

Section 7. Handling and Storage
Precautions Keep locked up Keep away from heat. Keep away from sources of ignition. Empty containers pose a fire risk,
evaporate the residue under a fume hood. Ground all equipment containing material. Do not ingest. Do not
breathe dust. Wear suitable protective clothing In case of insufficient ventilation, wear suitable respiratory
equipment If ingested, seek medical advice immediately and show the container or the label. Avoid contact with
skin and eyes
Storage Keep container dry. Keep in a cool place. Ground all equipment containing material. Keep container tightly
closed. Keep in a cool, well-ventilated place. Highly toxic or infectious materials should be stored in a separate
locked safety storage cabinet or room.

---

Section 8. Exposure Controls/Personal Protection
Engineering Controls Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below
recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
airborne contaminants below the exposure limit.
Personal Protection Splash goggles. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent.
Gloves.
Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
a Large Spill to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist
BEFORE handling this product.
Exposure Limits Not available.

---

Section 9. Physical and Chemical Properties
Physical state and appearance Solid. (Crystalline solid.) Odor Not available.
Taste Not available.
333.29 g/mole
Molecular Weight
Color Not available.
pH (1% soln/water) Not available.
Not available.
Boiling Point
Melting Point Decomposes. (147°C or 296.6°F)
Not available.
Critical Temperature
Specific Gravity Not available.
Vapor Pressure Not applicable.
Vapor Density Not available.
Volatility Not available.
Odor Threshold Not available.
Water/Oil Dist. Coeff. Not available.
Not available.
Ionicity (in Water)
Dispersion Properties See solubility in water.
Solubility Soluble in cold water.
Epinephrine bitartrate

---

Section 10. Stability and Reactivity Data
The product is stable.
Stability
Instability Temperature Not available.
Not available.
Conditions of Instability
Not available.
Incompatibility with various
substances
Corrosivity Non-corrosive in presence of glass.
Special Remarks on Not available.
Reactivity
Special Remarks on Not available.
Corrosivity
Polymerization No.

---

Section 11. Toxicological Information
Routes of Entry Dermal contact. Eye contact. Inhalation. Ingestion.
Toxicity to Animals Acute oral toxicity (LD50): 4 mg/kg [Mouse].
Chronic Effects on Humans The substance is toxic to lungs, the nervous system, mucous membranes.
Other Toxic Effects on Very hazardous in case of ingestion, of inhalation.
Humans Hazardous in case of skin contact (irritant, permeator).
Special Remarks on Not available.
Toxicity to Animals
Special Remarks on Not available.
Chronic Effects on Humans
Special Remarks on other Not available.
Toxic Effects on Humans

---

Section 12. Ecological Information
Ecotoxicity Not available.
BOD5 and COD Not available.
Products of Biodegradation Possibly hazardous short term degradation products are not likely. However, long term degradation products may
arise.
The products of degradation are more toxic.
Toxicity of the Products
of Biodegradation
Special Remarks on the Not available.
Products of Biodegradation
Epinephrine bitartrate

---

Section 13. Disposal Considerations
Waste Disposal

---

Section 14. Transport Information
DOT Classification CLASS 6.1: Poisonous material.
: Toxic solid, organic, n.o.s. (Epinephrine bitartrate) : UN2811 PG: III
Identification
Not available.
Special Provisions for
Transport
DOT (Pictograms)
HARMFUL
STOW AWAY
FROM
FOODSTUFFS
6

---

Section 15. Other Regulatory Information and Pictograms
TSCA 8(b) inventory: Epinephrine bitartrate
Federal and State
Regulations
California
Proposition 65
Warnings
Other Regulations OSHA: Hazardous by definition of Hazard Communication Standard (29 CFR 1910.1200).
CLASS D-1A: Material causing immediate and serious toxic effects (VERY TOXIC).
Other Classifications WHMIS (Canada)
CLASS D-2A: Material causing other toxic effects (VERY TOXIC).
DSCL (EEC) R36/38- Irritating to eyes and skin.
Health Hazard
HMIS (U.S.A.) 4 National Fire Protection
1 Flammability
1 Association (U.S.A.)
Fire Hazard
4 0 Reactivity
Health
Reactivity
0
Specific hazard
Personal Protection
E
WHMIS (Canada)
(Pictograms)
DSCL (Europe)
(Pictograms)
TDG (Canada)
(Pictograms)
6
Epinephrine bitartrate
ADR (Europe)
(Pictograms)
Protective Equipment
Gloves.
Lab coat.
Dust respirator. Be sure to use an
approved/certified respirator or
equivalent. Wear appropriate respirator
when ventilation is inadequate.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

生物活性

Epinephrine bitartrate（Adrenalinium）是一种α和β-肾上腺素能受体激动剂，其主要靶点包括：

• α2 肾上腺素能受体
• α-肾上腺素能受体
• β-肾上腺素能受体

用途

主要用于过敏性休克、支气管哮喘及心搏骤停的抢救。

类别与毒性分级

Epinephrine bitartrate属于有毒物品，具有剧毒性质。其急性毒性数据如下：

• 口服 - 小鼠 LD50: 4 毫克/公斤
• 腹腔注射 - 小鼠 LD50：0.78 毫克/公斤

危险特性

Epinephrine bitartrate具有可燃性，燃烧时会释放有毒的氮氧化物烟雾。

储运与灭火

应储存在通风良好、低温干燥的地方，并与其他食品原料分开存放。适宜的灭火剂包括干粉、泡沫、砂土、二氧化碳及雾状水。

反应信息

• 作为反应物：
  描述：

  (+/-)-Epinephrine bitartrate 在 N-乙酰基-L-半胱氨酸 作用下， 生成 Leukoadrenochrom 、 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  Raether; Lebus; Klopsch, Pharmazie, 1991, vol. 46, # 6, p. 426 - 431

  摘要：

  DOI：

文献信息

• Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients
  申请人：Rogers D. Robin

  公开号：US20070093462A1

  公开（公告）日：2007-04-26

  Disclosed are ionic liquids and methods of preparing ionic liquid compositions of active pharmaceutical, biological, nutritional, and energetic ingredients. Also disclosed are methods of using the compositions described herein to overcome polymorphism, overcome solubility and delivery problems, to control release rates, add functionality, enhance efficacy (synergy), and improve ease of use and manufacture.

  揭示了离子液体及制备活性药物、生物、营养和能量成分的离子液体组合物的方法。还揭示了利用本文描述的组合物的方法，以克服多型性、克服溶解度和输送问题、控制释放速率、增加功能性、增强功效（协同作用）以及改善易用性和制造工艺。
• Dendrimers as molecular translocators
  申请人：Goodman Murray

  公开号：US20060216265A1

  公开（公告）日：2006-09-28

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  转运分子包括一种树枝状聚合物和一种生物活性分子。这些转运分子的树枝状聚合物包括至少一个胍基团、至少一个质子化的胍基团、至少一个保护的胍基团、至少一个酰胺基团、至少一个质子化的酰胺基团、至少一个保护的酰胺基团、至少一个脲基团、至少一个质子化的脲基团、至少一个保护的脲基团、至少一个硫脲基团、至少一个质子化的硫脲基团，或至少一个保护的硫脲基团。生物活性分子与树枝状聚合物结合。一种增加药物生物利用度的方法包括将药物与本发明的树枝状聚合物结合。
• [EN] PROCESS FOR THE PREPARATION OF OPTICALLY ENRICHED ADRENALINE<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ADRÉNALINE ENRICHIE OPTIQUEMENT
  申请人：ROUVER INVEST S À R L

  公开号：WO2016038422A1

  公开（公告）日：2016-03-17

  A process for the production of (-)-adrenaline and (-)-adrenaline-L-tartrate is provided. The process provides for a new, efficient and commercially feasible process for the optical resolution of racemic adrenaline. In one aspect, a one pot process for the synthesis of (-)-adrenaline is provided. The process provides a simple and less expensive 5 process that can be used to prepare commercial scale batches of (-)-adrenaline and (-)-adrenaline-L-tartrate of API quality. The process avoids the use of expensive and unpredictable chiral catalysts.

  提供了一种生产(-)-肾上腺素和(-)-肾上腺素-L-酒石酸盐的过程。该过程提供了一种新的、高效且商业可行的对消旋肾上腺素进行光学分辨的方法。在一个方面，提供了一种合成(-)-肾上腺素的一锅法过程。该过程提供了一种简单且成本较低的方法，可用于制备符合API质量标准的商业规模批次的(-)-肾上腺素和(-)-肾上腺素-L-酒石酸盐。该过程避免了使用昂贵且不可预测的手性催化剂。
• CRYSTALLINE EPINEPHRINE MALONATE SALT
  申请人：Biothea Pharma, Inc.

  公开号：US20200031758A1

  公开（公告）日：2020-01-30

  Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.

  本文描述了肾上腺素盐，具体是肾上腺素丙二酸盐；以结晶形式存在的肾上腺素丙二酸盐；包含肾上腺素丙二酸盐的药物组合物；含有结晶形式的肾上腺素丙二酸盐的舌下或颊下药物组合物；以及一种治疗患者的方法，包括给患者使用含有结晶形式的肾上腺素丙二酸盐的药物组合物。
• [EN] HYPOGLYCEMIC DIHYDROPYRIDONES<br/>[FR] DIHYDROPYRIDONES HYPOGLYCÉMIQUES
  申请人：UNIV COLUMBIA

  公开号：WO2010016939A1

  公开（公告）日：2010-02-11

  The present invention provides, inter alia, a compound of formula I: wherein the substituent designations are indicated in the Specification. The present invention also provides pharmaceutical compositions comprising a compound of formula I, and methods of treatment or prevention of diabetes or hyperglycemia in a patient, and of normalizing blood glucose levels in a subject, by administering an effective amount of a compound of formula I.

  本发明提供了一种化合物，其化学式为I：其中取代基的指定如规范中所示。本发明还提供了包含化合物I的药物组合物，以及通过给予化合物I的有效量来治疗或预防糖尿病或高血糖的方法，并通过给予化合物I来使受试者的血糖水平正常化。

表征谱图